Consortium's goal is to create a comprehensive library of RNA interference reagents designed to reduce expression of specific genes, enabling scientists to elucidate their function
Sigma-Aldrich has entered into an agreement with the Massachusetts Institute of Technology (MIT) to serve as a scientific collaborator and distribution partner of the RNAi Consortium (TRC).
The consortium is based at the Broad Institute in Boston and comprises seven world-class research institutions and four commercial partners.
Over the next three years, this consortium's goal is to create a comprehensive library of RNA Interference (RNAi) reagents designed to reduce expression of specific human and mouse genes thereby enabling scientists to elucidate the function of the targeted gene.
In addition to participating as a sponsoring member of the consortium, Sigma-Aldrich will commercially distribute clones, purified DNA and viral stocks from the RNAi libraries, facilitating their use by researchers worldwide.
The consortium involves scientific collaborations between principal investigators at seven research institutions: Massachusetts General Hospital, Harvard Medical School, Dana-Farber Cancer Institute, The Broad Institute, Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, and Academia Sinica.
In addition to Sigma-Aldrich, TRC also includes corporate partners Bristol-Myers Squibb, Eli Lilly and Novartis.
"These 11 world-class entities will make common cause in a unique collaborative group to create a public good: a comprehensive set of reagents to be used in thousands of laboratories," said Eric Lander, director of the Broad Institute and one of TRC's principal investigators.
"In addition, the organisations will each benefit from sharing their expertise to advance the technology and to accelerate its systematic application in basic biomedical research and drug discovery".
RNAi is a natural cellular process that is involved in the regulation of gene expression.
In recent years scientists have developed methods that allow RNAi to be exploited as a research tool to decipher the function of particular genes.
The goal of the consortium is to create widely applicable RNAi research reagents that will enable biomedical researchers to discover the key genes underlying normal physiology as well as disease states.
It is widely believed that RNAi will revolutionise the way in which life science research is conducted and is expected to have a major impact on the understanding of the genetic basis of diseases such as cancer, arthritis and Alzheimer's.
"We are very excited to participate in the development of these reagents and to make them available to the entire biomedical research community," said Dave Julien, President of the biotechnology division at Sigma-Aldrich.
"This collaboration is a wonderful opportunity to participate in an important scientific undertaking while furthering our goal of providing cutting edge tools to enable life science research".
Participation in the generation and distribution of these critical RNAi reagents is the third phase of Sigma-Aldrich's new Functional Genomics initiative.
On 13 October 2004 the company announced its partnership with Ingex.
The two companies have worked together to make a revolutionary new gene disruption technology, the TargeTron gene knockout system, available to researchers studying the effect of a particular gene on a physiological pathway.
In contrast to RNA interference, this system allows a researcher to permanently turn off the targeted gene.
The second phase of the initiative, the planned acquisition of Proligo, was announced on 16 February 2005.
Proligo is a global supplier of key genomics research tools including custom DNA, custom RNA and phosphoramidite raw materials used for DNA and RNA synthesis.
The Proligo acquisition provides Sigma-Aldrich with one of only four exclusive licenses to a key Massachusetts Institute of Technology patent application that covers the use of synthetic RNA in RNA interference.
The addition of the consortium generated RNAi reagents to the Ingex partnership and the Proligo acquisition will position Sigma-Aldrich as a global leader in the exciting new area of functional genomics, tghe company believes.
